Home › Onyx Snubbing Amgen Paves Way for 89% Deal Premium: Real M&A
 

Keywords :   


Onyx Snubbing Amgen Paves Way for 89% Deal Premium: Real M&A

2013-07-02 19:26:33| Chemicals - Topix.net

Onyx Pharmaceuticals Inc., which surged more than 50 percent after rejecting a bid from Amgen Inc., is betting that potential suitors from Bayer AG to Bristol-Myers Squibb Co.

Tags: real ma premium deal

Category:Chemicals

Latest from this category

All news
18.06Tnemec Elevates Coatings Education with Newly Appointed AMPP CIP Instructor
18.06Joanna Gaines, KILZ Debut Magnolia Lakehouse Collection
18.06Advanced Polymer Coatings Launches TriFLEX for Rail Cars
17.06Chemours Appoints Shane Hostetter Chief Financial Officer
17.06Azelis Strengthens Footprint in South Africa Through Acquisition of CPS Chemicals (Coatings)
17.06The Powder Coating Institute Announces 2024 Hall of Fame Inductees
17.06Tremco CPG Celebrates Green Cohort From Rising Stars Program
17.06Vattenfall and BASF Sign Contract with Vestas for Latest 15 MW Offshore Wind Turbines in Germany
Chemicals »
18.06Tnemec Elevates Coatings Education with Newly Appointed AMPP CIP Instructor
18.06Next MANAchat Series is Scheduled for the Week of August 5
18.06Ruben Harris joins Flexcon as VP of supply chain
18.06Joanna Gaines, KILZ Debut Magnolia Lakehouse Collection
18.06Advanced Polymer Coatings Launches TriFLEX for Rail Cars
18.06Potential Tropical Cyclone One Graphics
18.06Potential Tropical Cyclone One Forecast Discussion Number 4
18.06Potential Tropical Cyclone One Forecast Advisory Number 4
More »